Contributing to the clinical phenomenon of aspirin sensitivity of PIK3CA-mutated CRC could also be increased formation of aspirin-triggered lipoxins and resolvins in COX-2-overexpressing tumors, which may also provide a promising explanation for different clinical outcomes of aspirin- and selective COX-2 inhibitor-treated patients suffering from PIK3CA-mutated CRC. This evidence concerns the gene PIK3CA and colorectal carcinoma.